<DOC>
	<DOCNO>NCT00471081</DOCNO>
	<brief_summary>The purpose study characterize safety immunogenicity 1 dose GSK134612 vaccine 12 month age GSK134612 vaccine administer 2 dos 9 12 month age .</brief_summary>
	<brief_title>Immunogenicity Safety Meningococcal Vaccine GSK134612 Given 1 2 Doses Healthy 9-12 Months Old Toddlers .</brief_title>
	<detailed_description>The protocol post amend reflect change consequence amendment protocol also comply FDA amendment Act , Sep 2007 . Sections impacted Brief Title , Official Title study , Brief Summary , Key Inclusion &amp; Exclusion criterion .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects whose parents/guardians investigator believe comply requirement protocol A male female 9 month age ( attained 10 month age ) time enrollment . Up date vaccination base ACIP recommendation standard practice investigational site . Written inform consent obtain parents/guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede enrollment , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 1 month dose study vaccine ( ) , exception influenza vaccine . Planned administration tetanus toxoid ( TT ) contain vaccine throughout active phase study ( one month last vaccination ) . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C W and/or Y . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History reaction allergic disease likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration active phase study ( one month last dose study vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neisseria meningitidis ;</keyword>
	<keyword>Humans ;</keyword>
	<keyword>Meningococcal vaccine ;</keyword>
	<keyword>Safety</keyword>
	<keyword>Vaccines , conjugate ;</keyword>
	<keyword>Toddlers ;</keyword>
	<keyword>Immunogenicity ;</keyword>
</DOC>